Abstract
The ectodomain of influenza A matrix protein 2 (M2e) is a candidate for a universal influenza A vaccine. We used recombinant Hepatitis B core antigen to produce virus-like particles presenting M2e (M2e-VLPs). We produced the VLPs with and without entrapped nucleic acids and compared their immunogenicity and protective efficacy. Immunization of BALB/c mice with M2e-VLPs containing nucleic acids induced a stronger, Th1-biased antibody response compared to particles lacking nucleic acids. The former also induced a stronger M2e-specific CD4(+) T cell response, as determined by ELISPOT. Mice vaccinated with alum-adjuvanted M2e-VLPs containing the nucleic acid-binding domain were better protected against influenza A virus challenge than mice vaccinated with similar particles lacking this domain, as deduced from the loss in body weight following challenge with X47 (H3N2) or PR/8 virus. Challenge of mice that had been immunized with M2e-VLPs with or without nucleic acids displayed significantly lower mortality, morbidity and lung virus titers than control-immunized groups. We conclude that nucleic acids present in M2e-VLPs correlate with improved immune protection.
Trial registration:
ClinicalTrials.gov NCT00819013.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adaptive Immunity*
-
Adaptor Proteins, Vesicular Transport / metabolism
-
Animals
-
Female
-
Humans
-
Immunity, Cellular
-
Influenza A Virus, H3N2 Subtype / immunology*
-
Influenza Vaccines / immunology*
-
Influenza Vaccines / metabolism
-
Influenza, Human / immunology
-
Influenza, Human / prevention & control
-
Lung / immunology
-
Lung / pathology
-
Lung / virology
-
Mice
-
Myeloid Differentiation Factor 88 / metabolism
-
Orthomyxoviridae Infections / immunology
-
Orthomyxoviridae Infections / prevention & control
-
RNA / metabolism*
-
Signal Transduction
-
Th1 Cells / immunology*
-
Vaccination
-
Vaccines, Virus-Like Particle / immunology*
-
Vaccines, Virus-Like Particle / metabolism
-
Viral Load
Substances
-
Adaptor Proteins, Vesicular Transport
-
Influenza Vaccines
-
M2e-HBc influenza vaccine
-
Myeloid Differentiation Factor 88
-
Vaccines, Virus-Like Particle
-
RNA
Associated data
-
ClinicalTrials.gov/NCT00819013
Grants and funding
L.I.I. was a beneficiary of the Belgian Federal Sciences Administration (Federale Wetenschapsbeleid, BELSPO) and was supported by Ghent University IOF-grant Stepstone IOF08/STEP/001 and Ghent University Special Research Grant BOF12/GOA/014. K.R. was supported by a predoctoral fellowship from Instituut voor de Aanmoediging van Innovatie door Wetenschap en Technologie (IWT). M.S. was a beneficiary of a “Bijzonder Onderzoeksfonds” research grant from Ghent University and B.S. is postdoctoral fellow with FWO-Vlaanderen. Research related to M2e-based influenza vaccines in the group of X.S. is supported by FWO-Vlaanderen project G.0375.10N, Ghent University IOF-grant Stepstone IOF08/STEP/001, and a research collaboration with Sanofi Pasteur. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.